+774.8%
VST vs MRNA
-70.5%
+845.3%
-48.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.7% | +0.7% | -3.4% | -2.7% |
| 7D | +2.0% | -8.2% | +10.2% | +2.3% |
| 30D | +1.5% | +125.6% | -124.1% | -4.6% |
| 3M | +6.3% | +197.1% | -190.8% | -2.8% |
| 6M | -10.3% | +148.5% | -158.8% | -17.0% |
| YTD | -8.6% | +363.3% | -371.9% | -20.1% |
| 1Y | -29.3% | +462.0% | -491.3% | -39.6% |
| 3Y | +344.9% | +26.9% | +318.0% | +313.2% |
| 5Y | +774.8% | -69.6% | +844.4% | +732.9% |
| All | +774.8% | -70.5% | +845.3% | +732.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling